Search - tctmd.com

Displaying 241 - 260 of 437

Sort: Relevancy | Date

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for September 2019

Shelley Wood

October 01, 2019

Off Script: A (Not So) Brief History of Aspirin’s Rise and Fall

News Opinion Off Script TCT 2019

Off Script: The TWILIGHT of Aspirin? A Brief History of ASA’s Rise and Fall

Kwan S. Lee

September 29, 2019

News Conference News ESC 2019

GRACE Risk Tool Fails to Increase Use of Guideline-Based Care After ACS: AGRIS

Yael L. Maxwell

September 10, 2019

News Conference News ESC 2019

Young MI Patients’ Ischemic Risk Extends at Least Two Decades

Caitlin E. Cox

September 06, 2019

News Daily News

Highest Risk, Biggest Benefit in ACS Patients Treated With Alirocumab: ODYSSEY OUTCOMES

Michael O'Riordan

August 26, 2019

News Daily News

Ezetimibe With Statin Therapy: Biggest Bang in Higher-Risk ACS Patients

Michael O'Riordan

August 22, 2019

News Conference News ESC 2019

ESC 2019: Antiplatelets in Diabetes, CAD and A-fib, an ARNI in HFpEF, Staged Complete PCI, and More

Shelley Wood

August 22, 2019

News Daily News

More Acute Stent Thrombosis With Synergy Stent in Bern PCI Registry

Michael O'Riordan

August 14, 2019

News Daily News

Retrospective Study Links Testosterone Therapy to Lower Mortality After MI, but Controversy Continues

Marcus A. Banks

July 31, 2019

News Daily News

CEC Identifies ‘Prognostically Important’ MIs: CHAMPION PHOENIX

Michael O'Riordan

July 30, 2019

News Daily News

Intensive Lipid-Lowering Slashes CVD in Elderly ACS Patients

Michael O'Riordan

July 19, 2019

News Daily News

Field in Flux: What’s the Best Antithrombotic Strategy for A-fib Patients Undergoing PCI?

Michael O'Riordan

July 03, 2019

News Conference News EAS 2019

Should Lp(a) Be Measured and Treated? Two Experts Hash Out Its Current Role

Michael O'Riordan

June 07, 2019

News Conference News EAS 2019

Absence of FH Diagnosis Linked to Increased Risk of Premature Mortality

Michael O'Riordan

June 05, 2019

News Conference News EAS 2019

Inclisiran Safe and Effective in Patients With Impaired Renal Function: ORION

Michael O'Riordan

June 04, 2019

News Conference News EAS 2019

FH Patients Derive Biggest Absolute Benefit From Statin Therapy: 4S Analysis

Michael O'Riordan

June 03, 2019

News Conference News EAS 2019

CHD Mortality Significantly Elevated in Patients With Severe FH

Michael O'Riordan

May 29, 2019

News Daily News

Familial Hypercholesterolemia Seen in 10% of Young MI Patients

Michael O'Riordan

May 15, 2019

News Daily News

PCSK9 Inhibitor Alirocumab Receives Expanded Indication for CV Event Reduction

Michael O'Riordan

April 29, 2019

News Daily News

Omega-3 PUFAs Offset Adverse CV Effects of Air Pollution in Small, Chinese Study

Michael O'Riordan

April 24, 2019

Advertisement

TCTMD’s Top 10 Most Popular Stories for September 2019

Off Script: The TWILIGHT of Aspirin? A Brief History of ASA’s Rise and Fall

GRACE Risk Tool Fails to Increase Use of Guideline-Based Care After ACS: AGRIS

Young MI Patients’ Ischemic Risk Extends at Least Two Decades

Highest Risk, Biggest Benefit in ACS Patients Treated With Alirocumab: ODYSSEY OUTCOMES

Ezetimibe With Statin Therapy: Biggest Bang in Higher-Risk ACS Patients

ESC 2019: Antiplatelets in Diabetes, CAD and A-fib, an ARNI in HFpEF, Staged Complete PCI, and More

More Acute Stent Thrombosis With Synergy Stent in Bern PCI Registry

Retrospective Study Links Testosterone Therapy to Lower Mortality After MI, but Controversy Continues

CEC Identifies ‘Prognostically Important’ MIs: CHAMPION PHOENIX

Intensive Lipid-Lowering Slashes CVD in Elderly ACS Patients

Field in Flux: What’s the Best Antithrombotic Strategy for A-fib Patients Undergoing PCI?

Should Lp(a) Be Measured and Treated? Two Experts Hash Out Its Current Role

Absence of FH Diagnosis Linked to Increased Risk of Premature Mortality

Inclisiran Safe and Effective in Patients With Impaired Renal Function: ORION

FH Patients Derive Biggest Absolute Benefit From Statin Therapy: 4S Analysis

CHD Mortality Significantly Elevated in Patients With Severe FH

Familial Hypercholesterolemia Seen in 10% of Young MI Patients

PCSK9 Inhibitor Alirocumab Receives Expanded Indication for CV Event Reduction

Omega-3 PUFAs Offset Adverse CV Effects of Air Pollution in Small, Chinese Study

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content